

## **REMARKS**

### **Status of the claims**

Claims 10 and 20 are pending in the application. All remaining claims have been cancelled. Claim 10 has been amended as suggested by the Examiner. As such, no new issues have been raised for consideration and entry of the amendments is respectfully requested.

### **Amendment to the Sequence Listing**

Submitted herewith is a substitute Sequence Listing. The substitute Sequence Listing corrects SEQ ID NOS: 14-17. Upon review of the specification, specifically Figure 23, Applicants noted that SEQ ID NOS: 14-17 begin at amino acid 516 and not amino acid 515 as erroneously listed. This correction in no way raises new issues, since the fragments are actually one amino acid shorter, thereby narrowing the scope of the claims. In addition, the deletion of one amino acid from the fragments that are clearly defined in Figure 23 should not raise any issues of enablement or written description under 35 U.S.C. §112, 1<sup>st</sup> paragraph or clarity under 35 U.S.C. §112, 2<sup>nd</sup> paragraph.

### **Rejection under 35 U.S.C. §112, 1<sup>st</sup> paragraph**

The Examiner maintains the rejection of claim 10 under 35 U.S.C. §112, 1<sup>st</sup> paragraph with the assertion that the specification does not enable the diagnosis of Alzheimer's through the quantitative determination of the peptides. Rather, the Examiner asserts that the specification is enabled for diagnosis through the co-localization of peptides with amyloid precursor protein (APP). Claim 10 has been amended in a manner believed to be suggested by the Examiner. Thus, claim has been amended to recite,

10. (Currently amended) A method for diagnosing Alzheimer's disease, comprising:  
obtaining a sample of brain tissue taken from a subject,  
determining ~~quantitatively the amount of~~ **co-localization of** the peptide according to claim 20 **with amyloid precursor protein (APP)** present in said sample,

wherein Alzheimer's disease is indicated when the co-localization amount  
~~of said peptide is greater than the amount of said peptide present~~ co-localization  
in a control non-Alzheimer's disease sample.

The rejection of claim 10 is thus believed to be overcome. If any issues remain with claim 10 or any other matters regarding the application, the Examiner is requested to please contact the undersigned.


In view of the above amendments and Remarks, Applicants believes the pending application is in condition for allowance.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact MaryAnne Armstrong, PhD, Reg. No. 40,069, at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37.C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Dated: March 5, 2010

Respectfully submitted,

By   
MaryAnne Armstrong, PhD  
Registration No.: 40,069  
BIRCH, STEWART, KOLASCH & BIRCH, LLP  
8110 Gatehouse Road  
Suite 100 East  
P.O. Box 747  
Falls Church, Virginia 22040-0747  
(703) 205-8000  
Attorney for Applicant

**Attachment:** Sequence Listing